GI Innovation Inc 358570
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ₩12,220.00
- Day Range
- ₩11,870.00–12,490.00
- 52-Week Range
- ₩8,115.00–15,650.00
- Bid/Ask
- ₩12,160.00 / ₩12,180.00
- Market Cap
- ₩540.30 Bil
- Volume/Avg
- 3,091 / 707,548
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 110.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
GI Innovation Inc is a bio-venture company that researches and develops protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and developing a fusion protein using the GI-SMART platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 81
- Website
- https://www.gi-innovation.com
Comparables
Valuation
|
Metric
|
358570
|
196170
|
011000
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 680.66 | — |
Price/Book Value | 17.52 | 97.88 | 2.30 |
Price/Sales | 110.23 | 197.58 | 4.82 |
Price/Cash Flow | — | 3,954.96 | — |
Price/Earnings
358570
196170
011000
Financial Strength
|
Metric
|
358570
|
196170
|
011000
|
|---|---|---|---|
Quick Ratio | 7.26 | 1.62 | 0.50 |
Current Ratio | 7.87 | 1.67 | 1.25 |
Interest Coverage | −117.67 | −10.35 | −69.66 |
Quick Ratio
358570
196170
011000
Profitability
|
Metric
|
358570
|
196170
|
011000
|
|---|---|---|---|
Return on Assets (Normalized) | −56.45% | −0.85% | −29.20% |
Return on Equity (Normalized) | −83.04% | −1.46% | −44.93% |
Return on Invested Capital (Normalized) | −61.24% | −3.30% | −33.91% |
Return on Assets
358570
196170
011000
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hpczbgvnbp | Yyxtl | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mkxmnssjk | Njfdkj | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ytzrjxcw | Wbqxw | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fwjwkgs | Phjkf | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Bvgrcbvd | Wrww | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Nkwhxwkfj | Xpm | $28.1 Bil | |||
| Moderna Inc
MRNA
| Vcrbqfmp | Gsbf | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Vjmwntst | Vcdl | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fpkjnfw | Qgjzmx | $13.4 Bil | |||
| Incyte Corp
INCY
| Sqjwfxb | Bgvgwss | $12.7 Bil |
United States